中国生物工程杂志

[1] Mount N M, Ward S J, Kefalas P, et al. Cell-based therapy technology classifications and translational challenges. Philos Trans R Soc Lond B Biol Sci,2015, 370(1680): 20150017.
[2] Garry G A, Garry D J. Somatic cell therapy for chronic heart failure: in search of mechanistic insights. J Card Fail, 2015,21(7):583-585.
[3] Kamigaki T, Ibe H, Okada S, et al. Improvement of impaired immunological status of patients with various types of advanced cancers by autologous immune cell therapy. Anticancer Res, 2015, 35(8):4535-4543.
[4] Fawaz F S, Hermiston T W, Dinter H. Allogeneic somatic cell therapy: process development challenges and future opportunities. Curr Opin Mol Ther,2010,12(4):383-385.
[5] Kamigaki T, Matsuda E, Okada S, et al. Prospective evaluation of safety of immune-cell therapy for patients with various types of advanced cancer. Anticancer Res,2014,34(8):4601-4607.
[6] Dunkin D, Mehandru S, Colombel J F. Immune cell therapy in IBD. Dig Dis, 2014,32(Suppl 1):61-66.
[7] Kim A, Shin D M, Choo M S. Stem cell therapy for interstitial cystitis/bladder pain syndrome. Curr Urol Rep,2016,17(1):1.
[8] Knoepfler P S. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Deliv Rev, 2015,82-83:192-196.
[9] Smith D C, Eisenberg P D, Manikhas G, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res, 2014,20(24):6295-6303.
[10] Gómez-Lechón M J, Lahoz A, Jiménez N, et al. Evaluation of drug-metabolizing and functional competence of human hepatocytes incubated under hypothermia in different media for clinical infusion. Cell Transplant,2008,17(8):887-897.
[11] Zheng Y W, Ohkohchi N, Taniguchi H. Quantitative evaluation of long-term liver repopulation and the reconstitution of bile ductules after hepatocellular transplantation. World J Gastroenterol,2005,11(39):6176-6181.
[12] van der Torren C R, Verrijn Stuart A A, Lee D, et al. Serum cytokines as biomarkers in islet cell transplantation for type 1 diabetes.PLoS One, 2016,11(1):e0146649.
[13] Ling Z, De Pauw P, Jacobs-Tulleneers-Thevissen D, et al. Plasma GAD65, a marker for early β-cell loss after intraportal islet cell transplantation in diabetic patients. J Clin Endocrinol Metab, 2015,100(6):2314-2321.
[14] Fotino N, Fotino C, Pileggi A. Re-engineering islet cell transplantation. Pharmacol Res,2015,98:76-85.
[15] Duif C, Koutah M A, Ackermann O, et al. Combination of autologous chondrocyte implantation (ACI) and osteochondral autograft transfer system (OATS) for surgical repair of larger cartilage defects of the knee joint. A review illustrated by a case report. Technol Health Care,2015,23(5):531-537.
[16] Yang L, Guo G, Niu X Y, et al. Dendritic cell-based immunotherapy treatment for glioblastoma multiforme. Biomed Res Int, 2015,2015:717530.
[17] Bregy A1, Wong T M, Shah A H, et al. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev,2013,39(8):891-907.
[18] Jkel C E, Vogt A, Gonzalez-Carmona M A, et al. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res,2014,2014:897214.
[19] Li Y, Meng F D, Tian X, et al. Impact of IL2 and IL2R SNPs on proliferation and tumorkilling activity of lymphokineactivated killer cells from healthy chinese blood donors. Asian Pac J Cancer Prev, 2014,15(18):79657970.
[20] Mackay-Sim A, Féron F. Clinical trials for the treatment of spinal cord injury: not so simple.Methods Mol Biol,2013,1059:229-237.
[21] Poglajen G, Vrtovec B.Stem cell therapy for chronic heart failure. Curr Opin Cardiol, 2015, 30(3):301-310.
[22] Kaji N, Baba Y. Nanobiodevice-based single biomolecule analysis, single-cell analysis, and in vivo imaging for cancer diagnosis, cancer theranostics, and iPS cell-based regenerative medicine. Anal Sci,2014,30(9):859-864.
[23] Freedman B S. Modeling kidney disease with iPS cells. Biomark Insights, 2015,10(Suppl 1):153-169.